Blood Res 2017; 52(2):
Published online June 22, 2017
https://doi.org/10.5045/br.2017.52.2.95
© The Korean Society of Hematology
1Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
2Department of Internal Medicine, Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong, Korea.
Correspondence to : Soo-Mee Bang, M.D., Ph.D. Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, 82, Gumi-ro 173 beon-gil, Bundang-gu, Seongnam 13620, Korea. smbang7@snu.ac.kr
Dapsone has been recommended as a second-line immunosuppressive agent for patients with immune thrombocytopenia (ITP).
We retrospectively analyzed the efficacy and safety of dapsone therapy in patients with ITP.
Nine ITP patients were treated with dapsone at a dose of 50?100 mg/day between May 2013 and March 2016. All patients were refractory to multiple previous treatments, with a median of 7 agents (range, 4?8), and 3 patients had undergone a previous splenectomy. The median pre-treatment platelet count was 4×109/L (range, 3?27×109/L). Only 1 patient (11.1%) responded to dapsone therapy. No severe adverse events were observed, except for 1 case of dapsone hypersensitivity syndrome.
Although dapsone is still useful for some patients, it may be ineffective in heavily pretreated patients with profound thrombocytopenia.
Keywords Immune thrombocytopenia, Dapsone, Efficacy, Toxicity
Blood Res 2017; 52(2): 95-99
Published online June 22, 2017 https://doi.org/10.5045/br.2017.52.2.95
Copyright © The Korean Society of Hematology.
Ji Yun Lee1, Jeong-Ok Lee1, Joo Young Jung2,#*, and Soo-Mee Bang1,#
1Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
2Department of Internal Medicine, Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong, Korea.
Correspondence to:Soo-Mee Bang, M.D., Ph.D. Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, 82, Gumi-ro 173 beon-gil, Bundang-gu, Seongnam 13620, Korea. smbang7@snu.ac.kr
Dapsone has been recommended as a second-line immunosuppressive agent for patients with immune thrombocytopenia (ITP).
We retrospectively analyzed the efficacy and safety of dapsone therapy in patients with ITP.
Nine ITP patients were treated with dapsone at a dose of 50?100 mg/day between May 2013 and March 2016. All patients were refractory to multiple previous treatments, with a median of 7 agents (range, 4?8), and 3 patients had undergone a previous splenectomy. The median pre-treatment platelet count was 4×109/L (range, 3?27×109/L). Only 1 patient (11.1%) responded to dapsone therapy. No severe adverse events were observed, except for 1 case of dapsone hypersensitivity syndrome.
Although dapsone is still useful for some patients, it may be ineffective in heavily pretreated patients with profound thrombocytopenia.
Keywords: Immune thrombocytopenia, Dapsone, Efficacy, Toxicity
Platelet count during dapsone treatment of
Clinical feature of a patient with dapsone hypersensitivity syndrome.
Table 1 . Patient data and results of dapsone treatment for immune thrombocytopenia..
a)Patient remained on dapsone for 39.3 months. b)Response defined as platelet count ≥30×109/L and at least 2-fold increase over the baseline count and absence of bleeding..
Abbreviations: F, female; M, male; TPO-RA,thrombopoietin-receptor agonist..
Table 2 . A summary of studies on dapsone therapy in patients with ITP..
a)Forty patients were found to have primary ITP. b)Sixteen patients were found to have primary ITP. c)Response to dapsone was defined as a platelet count >50×109/L..
Abbreviations: CR, complete response (>10×109/L); ITP, immune thrombocytopenia; NR, no response (<5×109/L); PR, partial response (5–10×109/L); R, response (>5×109/L)..
Doaa Mohamed El Demerdash, Maha Mohamed Saber, Alia Ayad, Kareeman Gomaa and Mohamed Abdelkader Morad
Blood Res 2024; 59():Dae Sik Kim
Blood Res 2022; 57(S1): S112-S119Young Hoon Park, Dae-Young Kim, Seongkoo Kim, Young Bae Choi, Dong-Yeop Shin, Jin Seok Kim, Won Sik Lee, Yeung-Chul Mun, Jun Ho Jang, Jong Wook Lee, Hoon Kook, on behalf of Korean Aplastic Anemia Working Party
Blood Res 2022; 57(1): 20-28
Platelet count during dapsone treatment of
Clinical feature of a patient with dapsone hypersensitivity syndrome.